Despite midstage trial miss, Amgen and AstraZeneca see promise for Tezspire in COPD

Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). But a second biologic treatment could be on its heels in the indication.